Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 5/20 | 1.00 |
| ▸ | AVPR2 known ✓ | P30518 | 3/20 | 1.00 |
| ▸ | AVPR1B known ✓ | P47901 | 3/20 | 1.00 |
| ▸ | OXTR | P30559 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL22511 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29454824 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29935850 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL1172203 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL1171610 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL29688276 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL17874853 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL31061295 | 0.93 | AVPR2 (0.87) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633737-A1 | USES OF AVPR1A AGONISTS | Viage Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-3787596-B1 | IMPROVED PHARMACEUTICAL FORMULATIONS | FERRING BV (NL) | 2025-06-25 | — | — | EP | claimed |
| CN-111412968-B | Weighing strain sensor signal magnitude transmission circuit, key unit and transmission method | 哈尔滨理工大学 | 2024-08-23 | — | — | CN | claimed |
| WO-2024130011-A1 | USES OF AVPR1A AGONISTS | VIAGE THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |
| CN-114076388-A | Automatic detection of suspected variable air volume units | 江森自控泰科知识产权控股有限责任合伙公司 | 2022-02-22 | — | — | CN | claimed |
| US-20220049868-A1 | SYSTEM AND METHOD FOR AUTOMATIC DETECTION AND CLUSTERING OF VARIABLE AIR VOLUME UNITS IN A BUILDING MANAGEMENT SYSTEM | Johnson Controls Tyco IP Holdings LLP (US) | 2022-02-17 | — | — | US | claimed |
| US-20260133188-A1 | NANOBIOSENSORS AND METHODS FOR DETECTION AND MEASUREMENT USING NANOBIOSENSORS | UNIV COLUMBIA (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4698566-A2 | AGNONISTIC ANTIBODIES TARGETING JAML | La Jolla Institute for Immunology (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12545946-B2 | Method for predicting the response of melanoma patients to a medicament | PAMGENE BV (NL) | 2026-02-10 | — | — | US | disclosed |
| EP-4633737-A1 | USES OF AVPR1A AGONISTS | Viage Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12435893-B2 | System and method for automatic detection and clustering of variable air volume units in a building management system | TYCO FIRE & SECURITY GMBH (CH) | 2025-10-07 | — | — | US | disclosed |
| EP-3436598-B1 | METHOD FOR PREDICTING THE RESPONSE OF MELANOMA PATIENTS TO A MEDICAMENT | PAMGENE BV (NL) | 2025-01-08 | — | — | EP | disclosed |
| CN-117625785-A | T lymphoblastic leukemia/lymphoma detection kit based on bioinformatics and serology | 天津医科大学总医院 | 2024-03-01 | — | — | CN | disclosed |
| CN-113916225-B | Combined navigation coarse difference robust estimation method based on steady weight factor coefficient | 哈尔滨工业大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-114459472-B | Combined navigation method of volume Kalman filter and discrete gray model | 上海海事大学 | 2023-07-04 | — | — | CN | disclosed |
| EP-4139089-A1 | ABRASIVE ARTICLES AND METHODS FOR FORMING SAME | Saint-gobain Abrasives, Inc (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220118046-A1 | METHODS COMPRISING DESMOPRESSIN | FERRING B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| CN-114076388-A | Automatic detection of suspected variable air volume units | 江森自控泰科知识产权控股有限责任合伙公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220049868-A1 | SYSTEM AND METHOD FOR AUTOMATIC DETECTION AND CLUSTERING OF VARIABLE AIR VOLUME UNITS IN A BUILDING MANAGEMENT SYSTEM | Johnson Controls Tyco IP Holdings LLP (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545946-B2 | Method for predicting the response of melanoma patients to a medicament | CD274, PDCD1, PDCD1LG2 | AVPR1A 3775/4885AVPR2 4173/4885AVPR1B 3027/4885 |
| US-20260133188-A1 | NANOBIOSENSORS AND METHODS FOR DETECTION AND MEASUREMENT USING NANOBIOSENSORS | ADAR, MTREX, RNGTT | AVPR1A 1709/4885AVPR2 2523/4885AVPR1B 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.